BIO-RAD LABORATORIES, INC.
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders' Equity
| Common Stock | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total Stockholders' Equity | |
|---|---|---|---|---|---|---|
| Balance at December 31, 2025 | $— | $476.0 | $(1,009.6) | $8,176.3 | $(189.1) | $7,453.6 |
| Net income (loss) | — | — | — | (527.1) | — | (527.1) |
| Other comprehensive income (loss), net of tax | — | — | — | — | (46.3) | (46.3) |
| Stock compensation expense | — | 15.0 | — | — | — | 15.0 |
| Purchase of treasury stock | — | — | (47.3) | — | — | (47.3) |
| Reissuance of treasury stock | — | (1.0) | 4.4 | — | — | 3.4 |
| Option premium received for structured purchases of treasury stock | — | 0.5 | — | — | — | 0.5 |
| Excise tax on stock repurchase | — | — | (0.5) | — | — | (0.5) |
| Balance at March 31, 2026 | $— | $490.5 | $(1,053.0) | $7,649.2 | $(235.4) | $6,851.3 |
| Net income (loss) | — | — | — | 371.4 | — | 371.4 |
| Other comprehensive income (loss), net of tax | — | — | — | — | (35.9) | (35.9) |
| Stock compensation expense | — | 14.5 | — | — | — | 14.5 |
| Purchase of treasury stock | — | — | (31.2) | — | — | (31.2) |
| Shares withheld related to net share settlement of equity awards | — | (0.1) | — | — | — | (0.1) |
| Excise tax on stock repurchase | — | — | (0.3) | — | — | (0.3) |
| Reissuance of treasury stock | — | (2.0) | 6.2 | — | — | 4.2 |
| Balance at June 30, 2026 | $— | $502.9 | $(1,078.3) | $8,020.6 | $(271.3) | $7,173.9 |
| Common Stock | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total Stockholders' Equity | |
|---|---|---|---|---|---|---|
| Balance at December 31, 2024 | $— | $463.2 | $(772.1) | $7,416.4 | $(538.2) | $6,569.3 |
| Net income (loss) | — | — | — | 64.0 | — | 64.0 |
| Other comprehensive income (loss), net of tax | — | — | — | — | 128.4 | 128.4 |
| Stock compensation expense | — | 15.3 | — | — | — | 15.3 |
| Purchase of treasury stock | — | — | (100.9) | — | — | (100.9) |
| Reissuance of treasury stock | — | (2.8) | 7.1 | — | — | 4.3 |
| Excise tax on stock repurchase | — | — | (1.0) | — | — | (1.0) |
| Balance at March 31, 2025 | $— | $475.7 | $(866.9) | $7,480.4 | $(409.8) | $6,679.4 |
| Net income (loss) | — | — | — | 317.8 | — | 317.8 |
| Other comprehensive income (loss), net of tax | — | — | — | — | 255.7 | 255.7 |
| Stock compensation expense | — | 11.9 | — | — | — | 11.9 |
| Purchase of treasury stock | — | — | (138.8) | — | — | (138.8) |
| Excise tax on stock repurchase | — | — | (1.4) | — | — | (1.4) |
| Shares withheld related to net share settlement of equity awards | — | (0.1) | — | — | — | (0.1) |
| Reissuance of treasury stock | — | (2.9) | 7.1 | — | — | 4.2 |
| Balance at June 30, 2025 | $— | $484.6 | $(1,000.0) | $7,798.2 | $(154.1) | $7,128.7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.